Daily Respiratory Research Analysis
Three respiratory studies stood out today: a Nature Biomedical Engineering report introduces an immune-competent human lung-on-a-chip that recapitulates severe influenza immune responses and reveals opposing roles of IL-1β and TNF-α plus a key CXCL12–CXCR4 axis. An Advanced Science paper uncovers a homocysteine–STX17–autophagy pathway driving pulmonary fibrosis and shows folate can rescue autophagy and fibrosis in vivo. A multicenter Critical Care Medicine cohort links ICU process-of-care and st
Summary
Three respiratory studies stood out today: a Nature Biomedical Engineering report introduces an immune-competent human lung-on-a-chip that recapitulates severe influenza immune responses and reveals opposing roles of IL-1β and TNF-α plus a key CXCL12–CXCR4 axis. An Advanced Science paper uncovers a homocysteine–STX17–autophagy pathway driving pulmonary fibrosis and shows folate can rescue autophagy and fibrosis in vivo. A multicenter Critical Care Medicine cohort links ICU process-of-care and structure to large between-hospital variability in VAP and CLABSI rates, identifying modifiable targets.
Research Themes
- Human organ-on-chip modeling of severe respiratory viral disease
- Metabolic-epigenetic control of autophagy in pulmonary fibrosis and therapeutic rescue
- ICU process-of-care determinants of device-associated infections (VAP, CLABSI)
Selected Articles
1. An immune-competent lung-on-a-chip for modelling the human severe influenza infection response.
A microvascularized, immune-competent human lung-on-a-chip recapitulated key features of severe H1N1 infection, including cytokine storm and epithelial injury. The study identified opposing roles of IL-1β and TNF-α and a stromal–immune CXCL12–CXCR4 axis as critical regulators, offering mechanistic targets for therapy development.
Impact: This scalable human-relevant platform closes a key translational gap by faithfully modeling severe influenza immune pathology and revealing druggable pathways. It enables preclinical testing of antivirals, immunomodulators, and vaccines with human mechanistic readouts.
Clinical Implications: While not directly practice-changing, the model supports rational design of targeted immunomodulation (for example, balancing IL-1β and TNF-α signaling or disrupting CXCL12–CXCR4) and could de-risk therapies before clinical trials, potentially accelerating interventions for severe viral pneumonia.
Key Findings
- Developed an immune-competent, microvascularized human small-airway lung-on-a-chip that reproduces cytokine storm, immune cell activation, and epithelial damage during severe H1N1 infection.
- Demonstrated opposing roles of IL-1β and TNF-α in initiating and regulating the cytokine storm.
- Identified a critical stromal–immune CXCL12–CXCR4 interaction as a regulator of the host response.
Methodological Strengths
- Human-relevant microphysiological system integrating epithelium, endothelium, and immune cells.
- Mechanistic dissection of cytokine and chemokine axes with functional readouts of tissue injury.
Limitations
- In vitro platform lacks full systemic immune and neurohumoral interactions.
- Findings require validation across viral strains and in vivo/clinical settings.
Future Directions: Leverage the platform to test targeted immunomodulators (e.g., IL-1 blockers, TNF modulators, CXCR4 antagonists) and vaccine candidates, and integrate patient-derived cells to model inter-individual variability.
Severe influenza affects 3-5 million people worldwide each year, resulting in more than 300,000 deaths annually. However, standard-of-care antiviral therapeutics have limited effectiveness in these patients. Current preclinical models of severe influenza fail to accurately recapitulate the human immune response to severe viral infection. Here we develop an immune-competent, microvascularized, human lung-on-a-chip device to model the small airways, successfully demonstrating the cytokine storm, immune cell activation, epithelial cell damage, and other cellular- and tissue-level human immune responses to severe H1N1 infection. We find that interleukin-1β and tumour necrosis factor-α play opposing roles in the initiation and regulation of the cytokine storm associated with severe influenza. Furthermore, we discover the critical stromal-immune CXCL12-CXCR4 interaction and its role in immune response to infection. Our results underscore the importance of stromal cells and immune cells in microphysiological models of severe lung disease, describing a scalable model for severe influenza research. We expect the immune-competent human lung-on-a-chip device to enable critical discoveries in respiratory host-pathogen interactions, therapeutic side effects, vaccine potency evaluation, and crosstalk between systemic and mucosal immunity in human lung.
2. Homocysteine Exacerbates Pulmonary Fibrosis via Orchestrating Syntaxin 17 Homocysteinylation of Alveolar Type II Cells.
Multi-omics in patients and mechanistic mouse studies reveal that elevated homocysteine drives IPF by homocysteinylation-dependent degradation of STX17 in alveolar type II cells, impairing autophagy. Folate lowers pulmonary Hcy, restores STX17 and autophagic flux, and attenuates fibrosis, nominating a tractable metabolic–proteostasis axis.
Impact: This study defines a first-in-kind Hcy–STX17 proteostasis mechanism of IPF progression and demonstrates pharmacologic rescue with folate in vivo, linking a measurable metabolite to autophagy dysfunction and fibrosis.
Clinical Implications: Homocysteine could serve as a biomarker of fibrotic activity; folate supplementation merits clinical evaluation as adjunct therapy in IPF. Targeting homocysteinylation or stabilizing STX17 may open new antifibrotic strategies.
Key Findings
- Plasma and BALF homocysteine levels are elevated in IPF versus controls; AT2 cells are the primary site of Hcy metabolism with downregulated MTRR during fibrosis.
- MTRR knockdown worsens, while MTRR overexpression protects against bleomycin-induced fibrosis in mice.
- Exogenous Hcy accelerates fibrosis; folate lowers pulmonary Hcy, restores STX17 and autophagic flux, and ameliorates fibrosis.
- Mechanism: Hcy induces homocysteinylation-ubiquitination of STX17, triggering proteasomal degradation and autophagy impairment.
Methodological Strengths
- Integrated patient multi-omics (plasma/BALF, scRNA-seq, spatial transcriptomics) with in vivo genetic and pharmacologic mouse models.
- Mechanistic delineation of post-translational modification (homocysteinylation) linking metabolism to autophagy and fibrosis.
Limitations
- Predominantly preclinical; no randomized human intervention data yet on folate efficacy in IPF.
- Potential variability of Hcy pathways across IPF subtypes; optimal dosing/safety of folate in this population remains to be defined.
Future Directions: Prospective trials testing folate supplementation and/or agents that block homocysteinylation or stabilize STX17 in IPF; validate Hcy as a prognostic/therapeutic biomarker and explore patient stratification.
Idiopathic pulmonary fibrosis (IPF) is a lethal interstitial lung disease, marked by progressive extracellular matrix deposition, for which there are no effective treatments to halt disease progression. Although hyperhomocysteinemia is implicated in multiple pathological processes, its role in IPF remains largely unexplored. Through multiomics profiling of IPF patients, significantly elevated homocysteine (Hcy) concentrations in plasma and bronchoalveolar lavage fluid are identified compared to healthy controls. Single-cell RNA sequencing and spatial transcriptomics reveal alveolar type 2 epithelial cells as the primary site of Hcy metabolism, with downregulation of Hcy-catabolizing enzyme methionine synthase reductase (MTRR) during fibrotic progression. Genetic perturbation studies in murine models demonstrate that MTRR knockdown exacerbates bleomycin-induced mortality and fibrosis, whereas MTRR overexpression exerts protective effects. Furthermore, Hcy supplementation initiates and accelerates pulmonary fibrosis development, while folate administration reduces pulmonary Hcy levels and alleviates fibrosis. Mechanistically, it is revealed that pathogenic hyperhomocysteinemia induces homocysteinylation-ubiquitination cascades that modify Syntaxin 17 (STX17) posttranslationally, leading to its proteasomal degradation and consequent impairment of autophagic flux. Notably, pharmacological folate administration reverses STX17 depletion, restoring autophagic flux and mitigating pulmonary fibrosis in mouse models. These findings collectively establish a Hcy-STX17-proteostasis axis wherein excess homocysteinylation creates a self-reinforcing loop of autophagy dysfunction and fibrogenesis.
3. Institutional Risk Factors Associated With Healthcare-Associated Infections in Brazilian ICUs: A Nested Cohort Within the IMPACTO-MR Platform.
In 50 Brazilian ICUs, VAP incidence was 6.03/1,000 MV-days and CLABSI 1.63/1,000 CVC-days, with large between-hospital variability partly explained by hospital-level practices and structures. Prevention bundles, flexible family visitation, hand hygiene training, adequate staffing, and specific respiratory care workflows were linked to fewer infections.
Impact: Provides actionable, multicenter evidence from an LMIC setting that specific process-of-care and staffing structures reduce VAP/CLABSI, informing policy and quality improvement with high external validity.
Clinical Implications: Implement and audit prevention protocols, enhance hand hygiene training, ensure adequate nursing staffing, support nurse-led sedation titration and RT-led weaning, and consider flexible family visitation and dental care access to reduce device-associated infections.
Key Findings
- Across 50 ICUs, VAP incidence was 6.03 per 1,000 MV-days and CLABSI 1.63 per 1,000 CVC-days with substantial between-hospital variability (median rate ratios 4.39 and 3.53).
- Hospital-level fixed effects explained ~40–45% of variability; prevention protocols, flexible visitation, and hand hygiene training reduced both VAP and CLABSI.
- Lower CLABSI was associated with nursing staffing ratios, single-use gowns, and alcohol availability; lower VAP with nurse-led sedation titration, RT-led weaning, and dentist availability.
Methodological Strengths
- Large multicenter cohort with prospectively collected patient-level data and hospital-level covariates.
- Appropriate count models (negative binomial/Poisson) with adjustment for individual-level confounders and random/fixed effects.
Limitations
- Observational design limits causal inference; residual confounding possible.
- Definitions aligned to national guidance may differ from CDC/NHSN; generalizability beyond Brazil requires caution.
Future Directions: Test targeted quality-improvement bundles in pragmatic trials; quantify cost-effectiveness of staffing changes; adapt interventions to other LMIC settings.
OBJECTIVES: Healthcare-associated infections are common and potentially preventable, especially in low- and middle-income countries (LMICs), due to substandard staffing, structure, and process-of-care. We evaluated institutional risk factors associated with ventilator-associated pneumonia (VAP) and central line-associated bloodstream infection (CLABSI) rates. DESIGN: Multicenter cohort study. SETTING: Fifty Brazilian ICUs. PATIENTS: All patients admitted from September 2019 to December 2021 to the participating ICUs, exposed to at least 2 days of invasive mechanical ventilation (MV) or central venous catheter (CVC). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Individual patient data were prospectively collected, and cross-sectional hospital-level data were collected at baseline. VAP and CLABSI were reported in accordance with Brazilian regulatory agency guidance. Negative binomial or Poisson multiple regression were used to model risk factors, adjusted for individual-level covariates. Of 75,164 ICU admissions, there were 19,108 at-risk (≥ 48 hr of MV) patients with a total of 244,059 MV-days for a VAP incidence rate of 6.03 (95% CI, 5.73-6.35) per 1,000 MV-days. There were 26,560 patients with a total of 375,078 CVC-days for a CLABSI incidence rate of 1.63 per 1,000 CVC-days (95% CI, 1.51-1.77 per 1,000 CVC-days). The median rate ratios of hospital random-effects were 4.39 (95% CI, 2.72-6.06) for VAP and 3.53 (95% CI, 2.30-4.76) for CLABSI. Hospital-level fixed effects explained 39.9% (95% CI, 33.6-46.1%) of the between-hospital variability for VAP and 44.7% (95% CI, 35.0-54.5%) for CLABSI. Prevention protocols, flexible family visitation policies, and hand hygiene training were associated with reduced rates of VAP and CLABSI. Nursing staffing ratios, single-use gowns, and alcohol availability were associated with a lower CLABSI rate. Sedation titration by nurses, weaning by respiratory therapists, and dentist availability were associated with a lower rate of VAP. CONCLUSIONS: Processes-of-care and ICU structure measures are associated with the burden of VAP and CLABSI in LMICs.